140
Participants
Start Date
December 7, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
March 31, 2026
NP-G2-044 Monotherapy
1600 mg QD, 2000mg QD, and 2100 mg QD
Anti-PD-1 Therapy
previously initiated per standard of care, at a dose and frequency in accordance with the package insert
NP-G2-044 Combination therapy
1600 mg QD or 2100 mg QD
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
Virginia Commonwealth University - Massey Cancer Center, Richmond
RECRUITING
University of Florida (UF) - Shands Cancer Center, Gainesville
COMPLETED
University Hospitals Cleveland Medical Center, Cleveland
COMPLETED
University of Cincinnati (UC) - Cancer Institute, Cincinnati
COMPLETED
Indiana University (IU) Melvin and Bren Simon Cancer Center, Indianapolis
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
University of Kansas Cancer Center, Fairway
RECRUITING
University of Arkansas for Medical Sciences, Little Rock
RECRUITING
University of Texas Southwestern, Dallas
RECRUITING
Honor Health Research Institute, Scottsdale
RECRUITING
University of Arizona - Cancer Center, Tucson
RECRUITING
City of Hope, Duarte
RECRUITING
City of Hope Irvine Lennar, Irvine
RECRUITING
Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates, Newport Beach
RECRUITING
Nuvance Health, Norwalk
COMPLETED
Atlantic Health System - Morristown Medical Center, Morristown
Lead Sponsor
Novita Pharmaceuticals, Inc.
INDUSTRY